Parsaclisib
- Generic Name
- Parsaclisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22ClFN6O2
- CAS Number
- 1426698-88-5
- Unique Ingredient Identifier
- OS7097575K
- Background
Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT03538041
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
🇮🇹AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARIT� DI NOVARA, Novara, Italy
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT03424122
- Locations
- 🇺🇸
Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of Arizona Cancer Center - Out Pt., Tucson, Arizona, United States
🇺🇸Texas Oncology, Austin, Texas, United States
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 17
- Registration Number
- NCT03314922
- Locations
- 🇯🇵
Cancer Institute Hospital of Jfcr, Koto-ku, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
🇯🇵Nagoya City University Hospital, Nagoya, Japan
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 162
- Registration Number
- NCT03235544
- Locations
- 🇩🇪
Justus-Liebig University, Giessen, Germany
🇮🇹A.O.U. Di Modena - Policlinico, Modena, Italy
🇵🇱University Clinical Center, Gdansk, Poland
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 110
- Registration Number
- NCT03144674
- Locations
- 🇺🇸
Arizona Oncology Associates, Tempe, Arizona, United States
🇺🇸Sansum Clinic, Santa Barbara, California, United States
🇺🇸UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 126
- Registration Number
- NCT03126019
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States
🇺🇸Hattiesburg Clinic Hematology, Hattiesburg, Mississippi, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT03039114
- Locations
- 🇮🇹
UO Ematologia ASST Spedali Civili, Brescia, Italy
🇺🇸Clinical Research Alliance, Lake Success, New York, United States
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT02998476
- Locations
- 🇺🇸
Asclepes Research Centers, Weeki Wachee, Florida, United States
🇺🇸Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 74
- Registration Number
- NCT02718300
- Locations
- 🇺🇸
California Cancer Associates For Research and Excellence, Fresno, California, United States
🇺🇸Baylor Scott and White Research Institute, Dallas, Texas, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 159
- Registration Number
- NCT02646748
- Locations
- 🇺🇸
John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸Georgetown University Medical Center Lombardi CCC, Washington, District of Columbia, United States
🇺🇸The Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.